Oral and Maxillofacial Tumor
Conditions
Interventions
Interventionall group:Interventions were carried out during the patients' second and third chemotherapy hospitalizations. On the 1st, 2nd, and 3rd days of hospitalization, twice a day, 30 minutes each
Control group:During the chemotherapy cycle, patients will be hospitalized for chemotherapy. In addition to receiving routine care and health guidance, no other interventions to promote hematopoiesis
Sponsors
Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1.Comply with the diagnostic criteria for oral and oropharyngeal cancer pathology diagnosis standards set by the Chinese Stomatological Association and the 2022 Head and Neck Tumor Diagnosis and Treatment Guidelines by the Chinese Society of Clinical Oncology (CSCO), and have a definitive histopathological diagnosis of oral and maxillofacial tumors; 2. Be newly diagnosed and receiving first-line platinum-based chemotherapy; 3.Be aged 18 to 79 years old; 4.Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of =3 months; 5.Have no myelosuppression prior to chemotherapy; 6.Have no severe organic diseases of the heart, liver, kidneys, or other organs; 7. Have no psychiatric diseases or cognitive impairments, and be able to understand and comply with the study requirements; 8.Provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with hematological diseases or autoimmune diseases that significantly affect the hematopoietic system of the bone marrow; 2.Patients who cannot tolerate the drugs used in this study or the electrostimulation therapy, such as severe skin damage or infection; 3.Pregnant or breastfeeding women; 4. Other situations deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet count; | — |
Secondary
| Measure | Time frame |
|---|---|
| General demographic data:Gender, age, educational level, marital status, living situation, BMI, etc.;General clinical data:Tumor location, pathological type, disease course stage, chemotherapy regimen, comorbidities, current chemotherapy cycle, etc.;Quality of life;Other blood routine counts apart from platelet count, including post-intervention white blood cell count, absolute neutrophil count, red blood cell count, and hemoglobin concentration.; | — |
Countries
China
Contacts
Public ContactHou Lili
Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed